Intravoxel Incoherent Motion Metrics as Potential Biomarkers for Survival in Glioblastoma

Josep Puig1, Javier Sánchez-González2, Gerard Blasco1

  • 1Imaging Research Unit, Institut de Diagnostic per la Imatge (IDI), Girona Biomedical Research Institute (IDIBGI), Hospital Universitari Dr Josep Trueta, Girona, Spain.

Plos One
|July 9, 2016
PubMed
Abstract

Insights

Intravoxel incoherent motion (IVIM) MRI metrics, specifically perfusion fraction (f) and pseudodiffusion coefficient (D*) in contrast-enhancing regions, show promise for predicting 6-month survival in glioblastoma patients. Combining these IVIM metrics with treatment information offers high accuracy in survival prediction.

Area of Science:

  • Radiology
  • Oncology
  • Medical Imaging

Background:

  • Intravoxel incoherent motion (IVIM) MRI is a technique for measuring brain tumor perfusion.
  • Its clinical utility in predicting glioblastoma survival requires further investigation.

Purpose of the Study:

  • To assess the effectiveness of IVIM-derived metrics in predicting survival for patients with newly diagnosed glioblastoma.
  • To identify specific IVIM parameters and their thresholds associated with 6-month survival.

Main Methods:

  • Fifteen glioblastoma patients underwent MRI with diffusion-weighted imaging (DWI) at 13 b-values.
  • Parametric maps of diffusion coefficient (D), pseudodiffusion coefficient (D*), and perfusion fraction (f) were generated for contrast-enhancing (CER) and non-enhancing (NCER) regions.
  • Kaplan-Meier and Cox proportional hazards analyses were used to evaluate prognostic factors.

Main Results:

  • Perfusion fraction in contrast-enhancing regions (fCER) and pseudodiffusion coefficient in contrast-enhancing regions (D*CER) correlated with cerebral blood volume.
  • Optimal cutoffs for 6-month survival were identified as fCER > 9.86% and D*CER > 21.712 x10-3mm2/s.
  • Treatment was a significant prognostic factor (HR=5.484), and fCER combined with treatment predicted survival with 100% accuracy.

Conclusions:

  • IVIM-derived metrics, fCER and D*CER, are valuable biomarkers for predicting 6-month survival in newly diagnosed glioblastoma.
  • These IVIM parameters hold potential for clinical application in glioblastoma prognosis.